&w=3840&q=100)
Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
The pharmaceutical stock continued to trade higher on the bourses. At last check, Marksans Pharma shares were quoted at ₹183.27 per share, up 2.63 per cent from the previous close of ₹178.58 on the NSE. A combined total of 0.13 million equity shares of Marksans Pharma, estimated to be valued at ₹24.37 crore, exchanged hands on the NSE and BSE today.
Why are Marksans Pharma shares ruling higher on the bourses?
The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem Limited in the UK, had received marketing authorisation for three of its products.
"Our wholly owned subsidiary, Relonchem Limited in the UK, has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (UK MHRA) for the following products: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets, Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets, and Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets," Marksans Pharma said in a release.
About Marksans Pharma
Headquartered in Mumbai, Marksans Pharma is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets.
The company's key focus areas lie in both over-the-counter (OTC) and prescription drugs, with wide-ranging applications across therapeutic areas such as pain management, cough and cold, digestive health, cardiovascular (CVS), central nervous system (CNS), oncology, antidiabetics, and antibiotics, among others.
Marksans Pharma's manufacturing facilities in India, the USA, and the UK are approved by several leading regulatory agencies, including the USFDA, UK MHRA, and Australian TGA. Its product portfolio spans major therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterology, and antiallergics. The company markets its products globally.
As of August 18, 2025, the pharmaceutical company had a market capitalisation of ₹8,325.07 crore on the NSE.
Marksans Pharma share price history
Shares of Marksans Pharma have declined nearly 39 per cent year-to-date (YTD). In contrast, the benchmark Nifty50 has advanced nearly 5 per cent during the same period.
Marksans Pharma shares hit their 52-week high of ₹358.70 per share on the NSE on August 28, 2024, while the 52-week low of ₹171 was recorded on April 7, 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
4 hours ago
- Economic Times
Sebi floats consultation paper on prudential norms for derivatives on non-benchmark indices
Sebi issued a consultation paper on implementing new eligibility norms for derivatives on non-benchmark indices, proposing constituent limits and weight caps. Exchanges BSE and NSE favor adjusting existing indices with phased transitions to ensure smooth compliance. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Markets regulator Sebi on Monday issued a consultation paper on how to implement new eligibility norms for derivatives on non-benchmark indices . The paper follows a May 29 circular that mandated stricter prudential rules to ensure such indices remain broad-based and not overly per the circular, non-benchmark indices with derivatives must have at least 14 constituents, with the top constituent's weight capped at 20% and the combined weight of the top three limited to 45%. Weights must also follow a descending order across exchanges have been evaluating two options: Alternative A - Launch new indices that meet the criteria while continuing existing ones and Alternative B - Adjust the constituent structure and weights of existing which runs the Bankex index with 10 constituents and no ETF tracking, has preferred Alternative B, opting to adjust weights and constituents in one on the other hand, has two affected indices — Nifty Bank (12 constituents, Rs 34,251 crore AUM in ETFs) and Nifty Financial Services (20 constituents, Rs 511 crore AUM).After consulting with mutual funds and AMFI, NSE has also favored Alternative B, but recommended a phased glide-path approach to avoid disruptions, particularly given the large AUM in Nifty Bank the proposed glide path, adjustments in constituent weights would be carried out in up to four monthly tranches, ensuring a staggered and orderly has now invited comments from stakeholders on whether adjusting existing indices is the right approach and on the modalities of such weight adjustments. The deadline for submitting comments is September 8 via Sebi's online portal (link here) or through email.
Time of India
4 hours ago
- Time of India
Sebi floats consultation paper on prudential norms for derivatives on non-benchmark indices
Sebi issued a consultation paper on implementing new eligibility norms for derivatives on non-benchmark indices, proposing constituent limits and weight caps. Exchanges BSE and NSE favor adjusting existing indices with phased transitions to ensure smooth compliance. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Markets regulator Sebi on Monday issued a consultation paper on how to implement new eligibility norms for derivatives on non-benchmark indices . The paper follows a May 29 circular that mandated stricter prudential rules to ensure such indices remain broad-based and not overly per the circular, non-benchmark indices with derivatives must have at least 14 constituents, with the top constituent's weight capped at 20% and the combined weight of the top three limited to 45%. Weights must also follow a descending order across exchanges have been evaluating two options: Alternative A - Launch new indices that meet the criteria while continuing existing ones and Alternative B - Adjust the constituent structure and weights of existing which runs the Bankex index with 10 constituents and no ETF tracking, has preferred Alternative B, opting to adjust weights and constituents in one on the other hand, has two affected indices — Nifty Bank (12 constituents, Rs 34,251 crore AUM in ETFs) and Nifty Financial Services (20 constituents, Rs 511 crore AUM).After consulting with mutual funds and AMFI, NSE has also favored Alternative B, but recommended a phased glide-path approach to avoid disruptions, particularly given the large AUM in Nifty Bank the proposed glide path, adjustments in constituent weights would be carried out in up to four monthly tranches, ensuring a staggered and orderly has now invited comments from stakeholders on whether adjusting existing indices is the right approach and on the modalities of such weight adjustments. The deadline for submitting comments is September 8 via Sebi's online portal (link here) or through email.
Mint
5 hours ago
- Mint
GST revamp, S&P ratings upgrade fuel rally in Indian equities
Benchmark indices edged higher on Monday as the proposed goods and services tax (GST) revamp lifted hopes of boosting domestic consumption. Adding to the momentum were India's sovereign ratings upgrade and a temporary relief for countries importing Russian oil. The Nifty 50 index ended Monday at 24,876.95 points, up 1% or 245.65 points, its highest gain since 23 May. The Sensex closed 0.83% higher at 81,273.75 points. Chirag Mehta, chief investment officer at Quantum Mutual Fund, said that while the GST rationalization announced on 15 August could drive up consumption, in the near term reduced collections could strain government finances. However, the expectation is that stronger demand will eventually make India's economic growth more sustainable, he said. Consumption heavy sectoral indices gained on Monday. Nifty Auto closed 4.18% higher, Nifty consumer durables gained 3.38%, and Nifty Realty ended the day up 2.17%. 'With external conditions volatile, the government's focus is on strengthening internal demand which compliments earlier tax cuts and lower interest rates,' said Mehta. The reduction in GST slabs to two from four is expected to be supportive for sectors such as insurance, consumer durables, auto, and cement, said Aparna Shanker, CIO, equity, at The Wealth Company Mutual Fund. The proposed changes to the GST structure, however, could hurt demand in the short-run for the auto industry, other experts said. Uncertainty around when the new GST tax rates will be implemented may prompt customers to defer purchases, potentially affecting demand during regional festivals such as Ganesh Chaturthi in Maharashtra (end-August) and Onam in Kerala (late August to early September), said Kumar Rakesh, analyst–information technology and auto, BNP Paribas, in a report dated 18 August. Prolonged uncertainty could also lead to inventory challenges, as several manufacturers have begun building stock ahead of the festive period, he added. Prime Minister Narendra Modi on 15 August said the GST reforms would be implemented by Diwali, targeting a significant reduction in taxes on everyday items, as a 'Diwali gift' for the common man. A day earlier, 14 August, India won its first sovereign rating upgrade from S&P Global Ratings since 2007. Morgan Stanley said in a report dated 4 August that while a soft patch in earnings growth appeared to be fading, and despite a dovish central bank, investor confidence may hinge on greater clarity around the external environment and the GST rate rationalization. However, foreign institutional investors remain uncertain towards India. FIIs pulled out equities worth $182.9 billion in August and $285.2 billion in July, as per Bloomberg. As per an Asia Fund Manager Survey by BofA Global Research, within Asia, Japan continued to be the most favored market by a significant margin, with China leaping to the second spot, followed by Taiwan and Korea. India tumbled to the bottom of the pack, chiefly because of US President Donald Trump's proposed 50% tariff on Indian goods. On Monday, the Nifty Midcap index closed 1.9% higher at 21,267.05 while the Nifty Smallcap index climbed 1.33% to 16,878.7. For Nifty 50, the zone of 24,800-24,770 will act as an important support, while on the upside, the zone of 25,000-25,050 will act as a crucial hurdle, said Sudeep Shah, head–technical and derivatives research, SBI Securities. Any sustainable move above the 25,050 level will lead to a sharp upside rally up to the level of 25200, he added.
